Skip to main content

Table 1 Summary of positive phase 3 clinical trials of angiogenic inhibitors in patients with advanced hepatocellular carcinoma (HCC)

From: Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions

SorafenibSHARP [18]602First-line
Versus placebo
10.7 m5.5 m2%43% 
 ASIAPACIFIC [19]226First-line
Versus placebo
6.5 m2.8 m3.3%35.3% 
LenvatinibREFLECT [20]954First-line
Versus sorafenib
13.6 m8.9 m24.1, 1%CR75.5% 
RegorafenibRESORCE [21]573Second-line
Versus placebo
10.6 m3.2 m11%65%Exclusion of patients previously intolerant to sorafenib
CabozantinibCELESTIAL [22]707Second or third-line
Versus placebo
10.2 m5.2 m4%64%Inclusion of patients previously intolerant to sorafenib
RamucirumabREACH-2 (35)292Second-line
Versus placebo
8.5 m2.8 m4.6%59.9%Inclusion of patients with poor prognosis based on high alpha-foeto-protein levels
  1. CR complete response; DCR disease control rate; m months; mOS median overall survival; mPFS median progression-free-survival; N number of randomized patients; ORR objective response rate